AZD5423 is primarily investigated for its potential in treating inflammatory and respiratory diseases. It functions as a selective glucocorticoid receptor modulator, designed to deliver anti-inflammatory effects with potentially reduced side effects compared to traditional corticosteroids. This compound has been explored in the context of asthma and chronic obstructive pulmonary disease (COPD), where it aims to suppress airway inflammation while minimizing systemic glucocorticoid exposure. Its development focuses on improving therapeutic index through enhanced receptor selectivity and tissue targeting, particularly in the lungs. Although clinical development has been limited and discontinued in some phases, AZD5423 contributed to research on next-generation anti-inflammatory agents with better safety profiles.